Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of ...
BEDMINSTER, N.J., April 24, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that it presented …